| Angioedemas, Hereditary
Haegarda vs Orladeyo
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Haegarda vs Orladeyo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOrladeyo has a higher rate of injection site reactions vs Haegarda based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Orladeyo but not Haegarda, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Haegarda
Orladeyo
At A Glance
SC injection
Twice weekly
C1-esterase inhibitor
Oral
Once daily
Plasma kallikrein inhibitor
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 60 IU/kg by subcutaneous injection twice weekly (every 3 or 4 days); self- or caregiver-administered after reconstitution.
Angioedemas, Hereditary (adults and pediatric patients >=12 years) 150 mg capsule orally once daily with food; reduce to 110 mg once daily with food for moderate or severe hepatic impairment (Child-Pugh Class B or C).
Angioedemas, Hereditary (pediatric patients 2 to <12 years) Weight-based oral pellets once daily with food: 72 mg (12 to <24 kg), 96 mg (24 to <32 kg), 108 mg (32 to <40 kg), or 132 mg (>=40 kg); avoid use in moderate or severe hepatic impairment.
Contraindications
- Life-threatening hypersensitivity reactions, including anaphylaxis, to C1-INH preparations or any excipient
—
Adverse Reactions
Most common (>4%) injection site reactions, hypersensitivity, nasopharyngitis, dizziness
Most common (>=10%) Abdominal pain, vomiting, diarrhea, back pain, gastroesophageal reflux disease
Serious QTc interval prolongation (at supratherapeutic doses), transaminase elevations
Postmarketing Nausea
Pharmacology
C1-esterase inhibitor (C1-INH) is a serine protease inhibitor (serpin) that inactivates key proteases in the complement, fibrinolytic, and coagulation systems -- including C1r, C1s, factor XIIa, and plasma kallikrein -- thereby preventing bradykinin generation and reducing vascular permeability; HAEGARDA replaces the missing or malfunctioning C1-INH protein in HAE patients.
Plasma kallikrein inhibitor; berotralstat binds to and inhibits plasma kallikrein's proteolytic activity, thereby reducing bradykinin generation and preventing angioedema attacks in patients with HAE due to C1-inhibitor deficiency or dysfunction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Haegarda
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (9/12)
Orladeyo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Haegarda
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Orladeyo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Haegarda
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Orladeyo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HaegardaView full Haegarda profile
OrladeyoView full Orladeyo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.